Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
Cytarabine
Pfizer Healthcare Ireland
L01BC; L01BC01
Cytarabine
100 milligram(s)/millilitre
Solution for injection
Product subject to prescription which may not be renewed (A)
Pyrimidine analogues; cytarabine
Marketed
1990-05-21
Page 1 of 9 2021-0073341 PACKAGE LEAFLET INFORMATION FOR THE USER CYTARABINE 100 MG/ML SOLUTION FOR INJECTION CYTARABINE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Cytarabine Solution for Injection is and what it is used for 2. What you need to know before you use Cytarabine Solution for Injection 3. How to use Cytarabine Solution for Injection 4. Possible side effects 5. How to store Cytarabine Solution for Injection 6. Contents of the pack and information 1. WHAT CYTARABINE SOLUTION FOR INJECTION IS AND WHAT IT IS USED FOR Cytarabine Solution for Injection is an anti-cancer medicine. Treatment with an anti-cancer medicine is sometimes called cancer chemotherapy. Cytarabine Solution for Injection is used to treat some types of leukaemia (cancer affecting the blood) and lymphomas (cancer of the lymph glands). It may be used in combination with other anti-cancer medicines. You must talk to a doctor if you do not feel better or if you feel worse 2. WHAT YOU NEED TO KNOW BEFORE YOU USE CYTARABINE SOLUTION FOR INJECTION DO NOT USE CYTARABINE SOLUTION FOR INJECTION • if you are allergic to cytarabine or any of the other ingredients of this medicine (listed in section 6) • if the cell count in your blood report is very low due to some cause other than cancer, unless your doctor decides otherwise • if you have had severe effects on your brain (encephalopathy) are feeling increasing difficulties in body coordination after radiation treatment or treatment with another anticancer medicine Przeczytaj cały dokument
Health Products Regulatory Authority 18 August 2021 CRN009ZMP Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cytarabine 100 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml contains 100 mg of cytarabine. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection Clear, colourless, sterile solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Alone or in combination for the induction of clinical remission and/or maintenance therapy in patients with acute myeloid leukaemia, acute non-lymphoblastic leukaemias, lymphoblastic leukaemia, erythroleukaemia, blast crises of chronic myeloid leukaemia and non-Hodgkin lymphoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The following doses are given as a guide, but the clinician should consult relevant protocols for the appropriate dosage of cytarabine and other antineoplastic agents given in combination. Most doses are given in mg/kg but may be converted to doses related to surface area by the use of standard nomograms. REMISSION INDUCTION (ADULTS): _Continuous Dosing: _The usual dose in leukaemia, is 2 mg/kg by rapid intravenous injection daily for ten days. If after ten days neither therapeutic response nor toxicity has been observed, the dose may be increased to 4 mg/kg until a therapeutic response or toxicity is evident. Daily blood counts should be taken. Almost all patients can be carried to toxicity with these doses. Alternatively, 0.5 to 1 mg/kg may be infused daily in 1- 24 hours for ten days, and then at a rate of 2 m g/kg/day until toxicity i s observed . Continue totoxicity or until remission occurs . Results from one hour infusions have been satisfactory in the majority of patients. _Intermittent dosing: _Cytarabine may be given as intermittent IV doses of 3- 5 mg/kg daily, for five consecutive days. This course of treatment can be repeated after an interval of 2 t o 9 days, and repeated until the therapeutic response or toxicity is exhibited. Ev Przeczytaj cały dokument